Cytokinetics (NASDAQ:CYTK) EVP Sells 3,500 Shares

Posted by Geri Gentry on Jul 7th, 2026

Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) EVP Fady Ibraham Malik sold 3,500 shares of the company’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $86.62, for a total value of $303,170.00. Following the transaction, the executive vice president directly owned 153,902 shares in the company, valued at approximately $13,330,991.24. This trade represents a 2.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Fady Ibraham Malik also recently made the following trade(s):

On Tuesday, June 23rd, Fady Ibraham Malik sold 3,500 shares of Cytokinetics stock. The shares were sold at an average price of $79.51, for a total value of $278,285.00.
On Tuesday, June 9th, Fady Ibraham Malik sold 3,500 shares of Cytokinetics stock. The shares were sold at an average price of $67.98, for a total value of $237,930.00.
On Tuesday, May 5th, Fady Ibraham Malik sold 3,500 shares of Cytokinetics stock. The stock was sold at an average price of $77.37, for a total value of $270,795.00.
On Tuesday, April 21st, Fady Ibraham Malik sold 3,500 shares of Cytokinetics stock. The stock was sold at an average price of $65.69, for a total value of $229,915.00.

Cytokinetics Price Performance

Shares of NASDAQ CYTK traded down $0.01 during mid-day trading on Tuesday, reaching $85.56. 2,293,372 shares of the company’s stock traded hands, compared to its average volume of 2,244,265. The stock has a market cap of $10.65 billion, a P/E ratio of -12.51 and a beta of 0.42. Cytokinetics, Incorporated has a 1-year low of $32.89 and a 1-year high of $88.31. The business has a 50-day simple moving average of $75.37 and a 200 day simple moving average of $67.95.

Cytokinetics (NASDAQ:CYTK – Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported ($1.67) EPS for the quarter, hitting analysts’ consensus estimates of ($1.67). The company had revenue of $19.36 million for the quarter, compared to the consensus estimate of $8.52 million. During the same period in the prior year, the firm posted ($1.36) earnings per share. The business’s revenue for the quarter was up 1112.5% on a year-over-year basis. Equities research analysts anticipate that Cytokinetics, Incorporated will post -6.26 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Stifel Nicolaus raised their price objective on Cytokinetics from $98.00 to $108.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Leerink Partners reiterated an “outperform” rating on shares of Cytokinetics in a research note on Tuesday, March 10th. Barclays raised their price target on shares of Cytokinetics from $87.00 to $95.00 and gave the company an “overweight” rating in a research report on Monday, April 6th. HC Wainwright boosted their price target on shares of Cytokinetics from $136.00 to $140.00 and gave the stock a “buy” rating in a report on Monday, May 11th. Finally, UBS Group raised shares of Cytokinetics from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $69.00 to $115.00 in a research report on Monday, June 29th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $99.90.

Get Our Latest Stock Report on Cytokinetics

Institutional Investors Weigh In On Cytokinetics

Large investors have recently made changes to their positions in the business. Woodline Partners LP raised its stake in shares of Cytokinetics by 676.1% during the 3rd quarter. Woodline Partners LP now owns 1,647,725 shares of the biopharmaceutical company’s stock worth $90,559,000 after purchasing an additional 1,435,422 shares during the period. Norges Bank bought a new position in Cytokinetics during the fourth quarter valued at about $51,281,000. Deep Track Capital LP grew its position in Cytokinetics by 17.8% during the third quarter. Deep Track Capital LP now owns 4,300,000 shares of the biopharmaceutical company’s stock valued at $236,328,000 after buying an additional 650,000 shares during the period. Siren L.L.C. purchased a new stake in Cytokinetics during the first quarter worth about $40,466,000. Finally, Northwestern Mutual Wealth Management Co. increased its holdings in Cytokinetics by 151,987.4% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 565,765 shares of the biopharmaceutical company’s stock worth $35,949,000 after buying an additional 565,393 shares during the last quarter.

About Cytokinetics

(Get Free Report)

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.

Insider Buying and Selling by Quarter for Cytokinetics (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.